- HalioDx focuses on exploring and validating the performance of its proprietary diagnostic solutions in multiple cancer indications.
- HalioDx collaborates with a network of the most prestigious centers expert in cancer translational research in France.
HalioDx SAS, an immuno-oncology diagnostic company, announced the successful granting of two major research projects, funded from the French RHU program (Hospital-University Research in Health), in close collaboration with prestigious clinical research centers in France. HalioDx is proud to be involved in two on the ten innovative and large-scale research projects selected as French “Investments for the Future” through the third RHU Call for proposals.
The PIONeeR project (€ 8.5 million) aim is to understand and overcome the resistance to immunotherapy treatments that target the PD-1/PD-L1 interaction in the treatment of advanced lung cancers. These new therapies demonstrated considerable progress in the fight against several cancers including non-small cell lung cancer, but only 20 to 25% of the patients are fully responsive and to date, no alternative therapeutic solution has been validated for those that do not favorably respond to treatment. The project is led by Prof. Fabrice Barlesi from AP-HM (Marseille).
The MyProbe project (€ 9.3 million) aim is to develop effective assays to identify the 10% to 15% of early breast cancer patients that are at risk of metastatic relapse following initial treatment. The new assays will allow reduction of additional expensive and cumbersome treatments. MyProbe is led by Prof. Fabrice André from Gustave Roussy Cancer Center (Villejuif).
For these projects, HalioDx will bring its expertise in immuno-oncology biomarkers and diagnostics development, notably with its proprietary assays Immunoscore®, Halioseek®, Immunosign® but also with undisclosed other proprietary biomarker approaches.
Vincent FERT, CEO of HalioDx comments: “HalioDx is excited to be part of these two ambitious RHU projects gathering leading experts in selected and distinct cancers, as we are committed to demonstrate that our biomarker technology is broadly applicable in Immuno-oncology diagnostics. Indeed working in such a collaborative mode, on indications such as lung and breast cancers, with the support of major medical experts is essential to drive medical innovation for patient’s care. ”